International assurance, tax and advisory firm EY has launched a first-in-industry initiative to tie medicine payments to clinical and patient satisfaction outcomes.

Built using clinical artificial intelligence (AI) and blockchain thanks to two technology collaborations, the Health Outcomes Assessment platform will, according to EY, lead to “fairer reimbursement and access to novel treatments for patients”.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The project sees EY partner with AI provider Sensyne Health and blockchain developer Guardtime. The former will use AI to determine the impact of medicine on patient health, while the latter will ensure sensitive healthcare data is securely handled and entirely traceable.

“Payers, providers and pharma have long aspired to move toward value-based healthcare; this collaboration will make it possible,” said Mike Gault, CEO of Guardtime.

“Guardtime’s KSI blockchain technology will help ensure patient-level data visibility without compromising data privacy, helping to ensure all participants can collaborate securely and with confidence.”

Disrupting medicine payments by linking them to clinical outcomes

Together the technologies will provide a clear picture of the clinical impact and patient satisfaction particular medicines are having, allowing reimbursement to be paid in line with their benefits.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The plan to link medicine payments to clinical outcomes is extremely novel for the healthcare industry – in part because it previously was near impossible to successfully track and monitor at the level required. However, EY believes this technology will make the concept possible for the first time.

“We are delighted to be working to deliver the triple win: with life sciences companies increasing access to medicines, healthcare providers achieving greater efficiency and effectiveness and, most importantly, more patients getting better health outcomes,” said Dan Mathews, EY EMEIA life sciences leader.

“This is possible through the combination of novel technologies and a supporting commercial model that allows industry collaboration.”

“This new collaboration will position Sensyne at the center of a technology solution to one of the major challenges facing global healthcare – how to link reimbursement to the benefits provided to patients,” added Lord Paul Drayson, CEO of Sensyne Health.

“We look forward to working with EY, Guardtime and global pharmaceutical companies and payers to help deliver this new capability.”

Read more: How virtual healthcare is targeting a “huge transformation” in Indian medicine